Skip to main content
NCBI home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2018 Dec 19.
Published in final edited form as: Eur J Cancer. 2018 Sep 27;103:287. doi: 10.1016/j.ejca.2018.09.022

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]

Toni K Choueiri a,*, Colin Hessel b, Susan Halabi c, Ben Sanford d, M Dror Michaelson e, Olwen Hahn f, Meghara Walsh a, Thomas Olencki g, Joel Picus h, Eric J Small i, Shaker Dakhil j, Darren R Feldman k, Milan Mangeshkar b, Christian Scheffold b, Daniel George l,#, Michael J Morris k,#
PMCID: PMC6299293  NIHMSID: NIHMS1510825  PMID: 30270112

The authors regret there was an error on page 120. The paragraph should read as follows (the correction has been underlined):

As of the July 01, 2017, data cutoff date for OS with a median follow-up of 34.5 months (IQR 31.4–40.4), 90 deaths had occurred (43 of 79 patients in the cabozantinib group and 47 of 78 patients in the sunitinib group).

The authors would like to apologise for any inconvenience caused.

RESOURCES